Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs

Journal of Tissue Engineering and Regenerative Medicine

Volumn 5, Issue 9, 2011, Pages 684-694

  Fazekasova, H ^a   Lechler, Robert ^a   Langford, Kelly ^b   Lombardi, Giovanna ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Smith and Nephew Research Centre   (United Kingdom)

Author keywords

Allogeneic T cells; Placenta derived MSCs

Indexed keywords

BONE; CELL PROLIFERATION; FLOWCHARTING; STEM CELLS; T-CELLS;

ALLOGENIC T CELL; BONE MARROW; BONE MARROW MESENCHYMAL; CELL-BE; CELL/B.E; CELL/BE; IMMUNOMODULATORY; MARROW MESENCHYMAL STEM CELLS; MESENCHYMAL STEM CELL; PLACENTA-DERIVED MESENCHYMAL STEM CELL;

CELL CULTURE;

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; ENDOGLIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; T6 ANTIGEN; THY 1 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL; NORMAL HUMAN; PHENOTYPE; PLACENTA; PRIORITY JOURNAL; STEM CELL EXPANSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; X CHROMOSOME; Y CHROMOSOME;

EID: 80053152070     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.362     Document Type: Article

References (53)

1. Aggarwal S, Pittenger MF. 2005; Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4): 1815-1822.
2. Augello A, Tasso R, Negrini SM, et al. 2005; Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35(5): 1482-1490.
3. Barlow S, Brooke G, Chatterjee K, et al. 2008; Comparison of human placentaland bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 17(6): 1095-1107.
4. Bartholomew A, Sturgeon C, Siatskas M, et al. 2002; Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1): 42-48.
5. Batten P, Sarathchandra P, Antoniw JW, et al. 2006; Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 12(8): 2263-2273.
6. Battula VL, Treml S, Abele H, et al. 2007; Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation 76: 326-336.
7. Bernardo ME, Emons JA, Karperien M, et al. 2007; Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res 48(3): 132-140.
8. Brooke G, Rossetti T, Pelekanos R, et al. 2008; Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol 144: 571-579.
9. Bruder SP, Ricalton NS, Boynton RE, et al. 1998; Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res 13(4): 655-663.
10. Caplan AI. 1994; The mesengenic process. Clin Plast Surg 21(3): 429-435.
11. Chamberlain JR, Schwarze U, Wang PR, et al., 2004; Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303(5661): 1198-1201.
12. Chan JL, Tang KC, Patel AP, et al. 2006; Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ. Blood 107(12): 4817-4824.
13. Chang CJ, Yen ML, Chen YC, et al. 2006; Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-γ. Stem Cells 24(11): 2466-2477.
14. Dazzi F, Ramasamy R, Glennie S, et al., 2006; The role of mesenchymal stem cells in haemopoiesis. Blood Rev 20(3): 161-171.
15. Di Nicola M, Carlo-Stella C, Magni M, et al. 2002; Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10): 3838-3843.
16. Djouad F, Plence P, Bony C, et al. 2003; Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102(10): 3837-3844.
17. Eliopoulos N, Stagg J, Lejeune L, et al. 2005; Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 105(13): 4057-4065.
18. Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. 1974; Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17(4): 331-340.
19. Glennie S, Soeiro I, Dyson PJ, et al. 2005; Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7): 2721-2727.
20. Götherström C, Ringdén O, Tammik C, et al. 2004; Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 190(1): 239-245.
21. Grinnemo KH, Månsson A, Dellgren G, et al. 2004; Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardivasc Surg 127(5): 1293-3000.
22. Gronthos S, Zannettino AC, Hay SJ, et al. 2003; Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116(9): 1827-1835.
23. Honczarenko M, Le Y, Swierkowski M, et al. 2006; Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24(4): 1030-1041.
24. Huang W, La Russa V, Alzoubi A, et al. 2006; Interleukin-17A: a T cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24(6): 1512-1518.
25. Jackson L, Jones DR, Scotting P, et al. 2007; Adult mesenchymal stem cells: differentiation potential and therapeutic applications. J Postgrad Med 53(2): 121-127.
26. Jones BJ, Brooke G, Atkinson K, et al. 2007; Immunosuppression by placental indoleamine 2, 3-dioxygenase: a role for mesenchymal stem cells. Placenta 28(11): 1174-1181.
27. Jones S, Horwood N, Cope A, et al. 2007; The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 179(5): 2824-2831.
28. Kim DH, Yoo KH, Choi KS, et al. 2005; Gene expression profile of cytokine and growth factor during differentiation of bone marrow-derived mesenchymal stem cells. Cytokine 31(2): 119-126.
29. Klyushnenkova E, Mosca JD, Zernetkina V, et al. 2005; T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12(1): 47-57.
30. Krampera M, Glennie S, Dyson J, et al. 2003; Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101(9): 3722-3729.
31. Le Blanc K, Rasmusson I, Sundberg B, et al. 2004; Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419): 1439-1441.
32. Le Blanc K, Tammik C, Rosendahl K, et al. 2003a; HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31(10): 890-896.
33. Le Blanc K, Tammik L, Sundberg B, et al. 2003b; Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57(1): 11-20.
34. Liechty KW, MacKenzie TC, Shaaban AF, et al. 2000; Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6(11): 1282-1286.
35. Li CD, Zhang WY, Li HL, et al. 2005; Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res 15(7): 539-547.
36. + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90(4): 516-525.
37. Majumdar MK, Keane-Moore M, Buyaner D, et al. 2003; Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10(2): 228-241.
38. Mareschi K, Biasin E, Piacibello W, et al. 2001; Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 86(10): 1099-1100.
39. Muraglia A, Cancedda R, Quarto R, et al. 2000; Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 113(pt 7): 1161-1166.
40. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. 2006; Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108(6): 2114-2120.
41. Pereira RF, Halford KW, O'Hara MD, et al. 1995; Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 92(11): 4857-4861.
42. Pittenger MF, Mackay AM, Beck SC, et al. 1999; Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143-147.
43. Potian JA, Aviv H, Ponzio NM, et al. 2003; Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171(7): 3426-3434.
44. Prockop DJ. 1997; Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276(5309): 71-74.
45. Ramasamy R, Fazekasova H, Lam EW, et al. 2007; Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83(1): 71-76.
46. Rogers NJ, Lechler RI. 2001; Allorecognition. Am J Transpl 1(2): 97-102.
47. Sugaya K. 2003; Neuroreplacement therapy and stem cell biology under disease conditions. Cell Mol Life Sci 60(9): 1891-1902.
48. Suva D, Garavaglia G, Menetrey J, et al. 2004; Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells. J Cell Physiol 198(1): 110-118.
49. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. 1998; Embryonic stem cell lines derived from human blastocysts. Science 282(5391): 1145-1147.
50. Tse WT, Pendleton JD, Beyer WM, et al. 2003; Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75(3): 389-397.
51. Uccelli A, Moretta L, Pistoia V, et al. 2006; Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 36(10): 2566-2573.
52. Zappia E, Casazza S, Pedemonte E, et al. 2005; Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106(5): 1755-1761.
53. Zhang W, Ge W, Li C, et al. 2004; Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 13(3): 263-271.